These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30642555)

  • 21. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
    Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
    World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of plakophilin 3 in diffuse malignant pleural mesothelioma.
    Mašić S; Brčić L; Krušlin B; Šepac A; Pigac B; Stančić-Rokotov D; Jakopović M; Seiwerth S
    Histol Histopathol; 2018 Sep; 33(9):995-1004. PubMed ID: 29722422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The highlights of the 15th international conference of the international mesothelioma interest group - Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?
    Klebe S; Galateau Salle F; Bruno R; Brcic L; I Chen-Yost H; Jaurand MC
    Lung Cancer; 2022 Jan; 163():1-6. PubMed ID: 34864334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
    Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
    Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
    Armato SG; Labby ZE; Coolen J; Klabatsa A; Feigen M; Persigehl T; Gill RR
    Lung Cancer; 2013 Nov; 82(2):190-6. PubMed ID: 24018024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
    Hjerpe A; Abd-Own S; Dobra K
    Arch Pathol Lab Med; 2018 Aug; 142(8):893-901. PubMed ID: 30040460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
    Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions.
    Wong RM
    J Thorac Oncol; 2016 Oct; 11(10):1602-3. PubMed ID: 27663394
    [No Abstract]   [Full Text] [Related]  

  • 31. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
    Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
    [No Abstract]   [Full Text] [Related]  

  • 33. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
    Husain AN; Colby T; Ordonez N; Krausz T; Attanoos R; Beasley MB; Borczuk AC; Butnor K; Cagle PT; Chirieac LR; Churg A; Dacic S; Fraire A; Galateau-Salle F; Gibbs A; Gown A; Hammar S; Litzky L; Marchevsky AM; Nicholson AG; Roggli V; Travis WD; Wick M;
    Arch Pathol Lab Med; 2013 May; 137(5):647-67. PubMed ID: 22929121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
    Tandon RT; Jimenez-Cortez Y; Taub R; Borczuk AC
    Arch Pathol Lab Med; 2018 Feb; 142(2):236-242. PubMed ID: 29048219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteopontin is not a specific marker in malignant pleural mesothelioma.
    Paleari L; Rotolo N; Imperatori A; Puzone R; Sessa F; Franzi F; Meacci E; Camplese P; Cesario A; Paganuzzi M
    Int J Biol Markers; 2009; 24(2):112-7. PubMed ID: 19634115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the Accuracy of Mesothelioma Diagnosis in China.
    Guo Z; Carbone M; Zhang X; Su D; Sun W; Lou J; Gao Z; Shao D; Chen J; Zhang G; Hu J; Chen K; Wang F; Pass HI; Yu H; Napolitano A; Yang H; Mao W
    J Thorac Oncol; 2017 Apr; 12(4):714-723. PubMed ID: 28007630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updates on grading mesothelioma.
    Schulte JJ; Husain AN
    Histopathology; 2024 Jan; 84(1):153-162. PubMed ID: 37872123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
    Hirata T; Zheng Q; Chen Z; Kinoshita H; Okamoto J; Kratz J; Li H; Lui N; Do H; Cheng T; Tseng HH; Koizumi K; Shimizu K; Zhou HM; Jablons D; He B
    Oncol Rep; 2015 Apr; 33(4):2052-60. PubMed ID: 25632963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.
    Opitz I; Bueno R; Lim E; Pass H; Pastorino U; Boeri M; Rocco G;
    Eur J Cardiothorac Surg; 2014 Oct; 46(4):602-6. PubMed ID: 24623168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.